Creating better vaccines for influenza using a new immune booster
DEVELOPMENT OF VACCINES FOR INFLUENZA USING AN IMMUNO-MODULATOR ADJUVANT AND MULTI-PLATFORM APPROACH
This study is testing a new type of flu vaccine that includes special ingredients to boost your immune response, helping your body make more antibodies while keeping side effects low, so you can better fight off the flu.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10935797 on NIH RePORTER |
What this research studies
This research focuses on developing a new formulation of vaccines for influenza that includes an immune-modulating adjuvant. The goal is to enhance the vaccine's effectiveness by customizing the immune response, which can lead to higher antibody levels while minimizing inflammation and side effects. The researchers will combine a molecule called Bafetinib with another compound, INI-4001, to create a more effective adjuvant system. This approach aims to improve the overall performance of influenza vaccines through targeted modifications and rigorous testing.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of influenza, including those with weakened immune systems or chronic health conditions.
Not a fit: Patients who are not at risk for influenza or those who have already received a recent influenza vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective influenza vaccines that provide better protection with fewer side effects.
How similar studies have performed: Previous research has shown promise in enhancing vaccine efficacy through the use of novel adjuvants, indicating that this approach could yield significant advancements.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: El-Kammash, Bruxanne — University of Chicago
- Study coordinator: El-Kammash, Bruxanne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.